Related Experiment Video
Updated: May 18, 2026

Modeling Mitochondrial Disease Using Brain Organoids: A Focus on Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes
Published on: October 10, 2025
Molecular characterization of 355 mucopolysaccharidosis patients reveals 104 novel mutations
Laura M Pollard1, Julie R Jones, Tim C Wood
1Biochemical Diagnostic Laboratory, Greenwood Genetic Center, 106 Gregor Mendel Circle, Greenwood, SC 29646, USA. lpollard@ggc.org
Abstract:
Mucopolysaccharidosis (MPS) disorders are heterogeneous and caused by deficient lysosomal degradation of glycosaminoglycans, resulting in distinct but sometimes overlapping phenotypes. Molecular analysis was performed for a total of 355 MPS patients with MPSI (n = 15), MPSII (n = 218), MPSIIIA (n = 86), MPSIIIB (n = 20), MPSIVA (n = 6) or MPSVI (n = 10). This analysis revealed 104 previously unreported mutations: seven in IDUA (MPSI), 61 in IDS (MPSII), 19 in SGSH (MPSIIIA), 11 in NAGLU (MPSIIIB), two in GALNS (MPSIVA) and four in ARSB (MPSVI). The intergenic comparison of the mutation data for these disorders has revealed interesting differences. Whereas IDUA, IDS, NAGLU and ARSB demonstrate similar levels of mutation heterogeneity (0.6-0.675 different mutations per total alleles), SGSH and GALNS have lower levels of mutation heterogeneity (0.282 and 0.455, respectively), due to more recurrent mutations. The type of mutation also varies significantly by gene. SGSH, GALNS and ARSB mutations are usually missense (76.5 %, 81.8 % and 85 %), while IDUA has many more nonsense mutations (56 %) than the other genes (≤20%). The mutation spectrum is most diverse for IDS, including intergenic inversions and multi-exon deletions. By testing 102 mothers of MPSII patients, we determined that 22.5 % of IDS mutations are de novo. We report the allele frequency of common mutations for each gene in our patient cohort and the exonic distribution of coding sequence alterations in the IDS, SGSH and NAGLU genes, which reveals several potential "hot-spots". This further molecular characterization of these MPS disorders is expected to assist in the diagnosis and counseling of future patients.
Insights
This study identified 104 new mutations across six mucopolysaccharidosis (MPS) types in 355 patients, revealing gene-specific mutation patterns and heterogeneity. Findings aid in diagnosing and counseling MPS patients.
Area of Science:
- Biochemistry
- Genetics
- Rare Diseases
Background:
- Mucopolysaccharidosis (MPS) disorders are a group of rare genetic diseases.
- They result from deficiencies in lysosomal enzymes crucial for glycosaminoglycan degradation.
- This leads to the accumulation of these substances, causing various clinical phenotypes.
Purpose of the Study:
- To perform molecular analysis on a cohort of 355 MPS patients across six subtypes (MPSI, MPSII, MPSIIIA, MPSIIIB, MPSIVA, MPSVI).
- To identify and characterize novel mutations in the involved genes.
- To compare mutation heterogeneity, mutation types, and distribution across different MPS genes.
Main Methods:
- Conducted molecular analysis on 355 MPS patients.
- Identified mutations in IDUA, IDS, SGSH, NAGLU, GALNS, and ARSB genes.
- Analyzed mutation heterogeneity, mutation types (missense, nonsense), and exonic distribution.
- Determined de novo mutation rate in MPSII through maternal testing.
Main Results:
- Discovered 104 previously unreported mutations across the studied MPS genes.
- Observed significant differences in mutation heterogeneity and types between genes.
- IDUA gene showed a high proportion of nonsense mutations (56%), while SGSH, GALNS, and ARSB predominantly had missense mutations.
- Identified potential mutation 'hot-spots' in IDS, SGSH, and NAGLU genes.
- Found that 22.5% of IDS mutations in MPSII patients were de novo.
Conclusions:
- The molecular characterization provides valuable insights into the genetic basis of various MPS disorders.
- Understanding gene-specific mutation patterns aids in accurate diagnosis and genetic counseling for MPS.
- The identification of de novo mutations and mutation hotspots contributes to a deeper understanding of MPS etiology.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Lysosomal Hydrolases
Mutations
Single Nucleotide Polymorphisms-SNPs
Mutations in Microorganisms

